【药明合联(02268.HK)拟向控股股东药明生物(02269.HK)发行2413.4万股认购股份 净筹约14.14亿港元】智通财经APP讯，药明合联(02268.HK)公布，于2025年9月3日(联交所交易时段前)，该公司与认购人药明生物(02269.HK)订立认购协议，拟向认购人发行2413.4万股认购股份，认购价为每股认购股份58.85港元(与配售价相同)，总代价约为14.2亿港元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.